Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02927964 · ClinicalTrials.gov registry record · Phase 1
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
A Phase 1 study, sponsored by Robert Lowsky.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT02927964 is a Phase 1 study that has completed, run by Robert Lowsky. The registered enrollment target is 21 participants.
The verdict
NCT02927964, a Phase 1 study, has completed, sponsored by Robert Lowsky.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This phase Ib/II trial studies the side effects and best dose of toll-like receptor 9 (TLR9) agonist SD-101 when given together with ibrutinib and radiation therapy and to see how well they work in treating patients with Low Grade Follicular Lymphoma, Marginal Zone Lymphoma, or Mantle Cell Lymphoma that has come back after a period of improvement or no longer responds to treatment. Immunostimulants such as TLR9 agonist SD-101 may increase the ability of the immune system to fight infection and disease. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving TLR9 agonist SD-101 with ibrutinib and radiation therapy may induce an immune response and prolong anti-tumor response.
Interventions
- RADIATION Radiation Therapy
- DRUG Ibrutinib
- DRUG TLR9 Agonist SD-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-11-07 |
| Est. Completion | 2023-05-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02927964
The ClinicalTrials.gov registry entry for NCT02927964 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Robert Lowsky, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radiation Therapy is the first listed.
NCT02927964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02927964 about?
NCT02927964 is a clinical study titled "TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma". This phase Ib/II trial studies the side effects and best dose of toll-like receptor 9 (TLR9) agonist SD-101 when given together with ibrutinib and radiation therapy and to see how well they work in treating patients with Low Grade Follicular Lymphoma, Marginal Zone Lymphoma, or Mantle Cell Lymphoma ...
What is the current status of trial NCT02927964?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2016-11-07. Estimated completion is 2023-05-18.
What interventions are being tested in trial NCT02927964?
The interventions under investigation include: Radiation Therapy (RADIATION), Ibrutinib (DRUG), TLR9 Agonist SD-101 (DRUG).
Who is sponsoring clinical trial NCT02927964?
This trial is sponsored by Robert Lowsky, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.